Basel Medical Group Ltd (BMGL) Fair Value 2026

BMGL · Services-Offices & Clinics of Doctors of Medicine ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.0 /10

32 fundamental signals · 12 models active

Value Trap Risk

(—/100)

Quick Summary — As of 2026-07-13, Basel Medical Group Ltd (BMGL) trades at $6.41, approximately 62% below CirclFi’s Bayesian DCF fair value of $16.74. QOC: 8.0/10. 12/13 models active.

Key Facts

Ticker
BMGL
Price
$6.41
Quality Score
8.0/10
Value Trap Risk
—/100
Models Active
12/13
Last Updated
Strength: First Chicago suggests +215.1% upside with 34% confidence
Risk: Limited model coverage (12/13) may reduce confidence

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($6.41)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Medium Conviction
$16.74 +161.0%
Earnings Power Value
Medium Conviction
$15.15 +136.3%
CUCE Ensemble
Low Conviction
$14.57 +127.1%
First Chicago
Medium Conviction
$20.21 +215.1%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Basel Medical Group Ltd (BMGL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Basel Medical Group Ltd's intrinsic value is estimated at $11.13, suggesting a +73.5% average upside from the current price of $6.41. While 8 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: First Chicago targets $20.21 (+215.1%), versus Dynamic NAV at $0.01 (-99.9%). This +315.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About BMGL?

12 of 13 models are currently active for BMGL. Of these, 9 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates BMGL's intrinsic value at $16.74, implying +161.0% upside from the current price. See which stocks rank higher →

How Does BMGL Rank in Services-Offices & Clinics of Doctors of Medicine?

Among 8 Services-Offices & Clinics of Doctors of Medicine stocks, BMGL ranks #2 by Quality of Company score. CirclFi's QOC score of 8.0/10 evaluates 32 fundamental signals. A score of 8.0 places BMGL in the top tier.

Basel Medical Group Ltd operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BMGL a Value Trap?

The Value Trap algorithm is not active for BMGL. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Basel Medical Group Ltd. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Basel Medical Group Ltd earns a quality score of 8.0/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +315.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BMGL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BMGL's 12 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Basel Medical Group Ltd Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Services-Offices & Clinics of Doctors of Medicine Stocks Should You Also Analyze?

7 related Services-Offices & Clinics of Doctors of Medicine stocks with 13-model coverage

Read investment analysis: SBC · TDOC · HIMS · AUNA · LFMD

Frequently Asked Questions About Basel Medical Group Ltd

What is Basel Medical Group Ltd's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Basel Medical Group Ltd (BMGL) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $16.74. The Quality of Company score is 8.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BMGL overvalued or undervalued right now?

At $6.41, 9 of 12 active models suggest BMGL may be undervalued, while 3 indicate potential overvaluation. The assessment depends on which methodology best fits Basel Medical Group Ltd's business model in Services-Offices & Clinics of Doctors of Medicine.

What does a Quality of Company score of 8.0 mean for BMGL?

Basel Medical Group Ltd's QOC of 8.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on BMGL?

CirclFi analyzes BMGL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is BMGL a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for BMGL at this time. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on BMGL.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access